The pharmaceutical sector is characterized by a great oligopoly, with small and big transnational companies which operate in several countries and perform high levels of investment in research and development, which imply great barriers to the entry of new companies. Itâs a sector in which appropriation of knowledge occurs principally through the patent of new drugs. Such patents allow monopoly of the developer company of the product over the same product during a determined period. The possibility of abusive practices from this monopoly leads the authorities to take measures for the control of prices and to guarantee the finitude of the patent. Therefore, the United States and the European Union are pressuring the other countries for the establishment of new measures, which go beyond the TRIPS Agreement, such as secrecy of drugs registration, in order to enlarge the monopoly of big pharmaceutical companies and retard the entry of generics.@en
Array ( [dateOfAvailability] => Array ( [pt] => Array ( [0] => Array ( [2008-07-01] => 128168 ) ) ) [hasAuthor] => Array ( [nn] => Array ( [0] => Array ( [Lia Hasenclever] => 116166 ) [1] => Array ( [Julia Paranhos] => 130412 ) [2] => Array ( [Vitor Paiva] => 133160 ) ) ) [hasFileStorage] => Array ( [nn] => Array ( [0] => Array ( [_repository/127865/2019/12/oai_ojs_reciis_icict_fiocruz_br_article_848#00086.pdf] => 133161 ) ) ) [hasSubject] => Array ( [en] => Array ( [0] => Array ( [Intellectual property] => 272433 ) [1] => Array ( [Patent] => 271943 ) [2] => Array ( [Generics] => 133156 ) [3] => Array ( [Drug registration] => 133157 ) ) [pt] => Array ( [0] => Array ( [Propriedade intelectual] => 285182 ) [1] => Array ( [Patente] => 227476 ) [2] => Array ( [Genérico] => 133158 ) [3] => Array ( [Registro de medicamento] => 133159 ) ) ) [isPartOfSource] => Array ( [pt] => Array ( [0] => Array ( [Revista Eletrônica de Comunicação, Informação e Inovação em Saúde] => 127865 ) ) ) [hasIssueOf] => Array ( [pt] => Array ( [0] => Array ( [ISSUE:JNL:00086-2008-2-2] => 128164 ) ) ) [hasAbstract] => Array ( [en] => Array ( [0] => Array ( [The pharmaceutical sector is characterized by a great oligopoly, with small and big transnational companies which operate in several countries and perform high levels of investment in research and development, which imply great barriers to the entry of new companies. Itâs a sector in which appropriation of knowledge occurs principally through the patent of new drugs. Such patents allow monopoly of the developer company of the product over the same product during a determined period. The possibility of abusive practices from this monopoly leads the authorities to take measures for the control of prices and to guarantee the finitude of the patent. Therefore, the United States and the European Union are pressuring the other countries for the establishment of new measures, which go beyond the TRIPS Agreement, such as secrecy of drugs registration, in order to enlarge the monopoly of big pharmaceutical companies and retard the entry of generics.] => 0 ) ) [pt] => Array ( [0] => Array ( [O setor farmacêutico é caracterizado por um grande oligopólio, com poucas e grandes empresas transnacionais que atuam em diversos países e realizam altos níveis de investimento em pesquisa e desenvolvimento, que implicam em grandes barreiras à entrada de novas empresas. Trata-se de um setor em que a apropriação do conhecimento ocorre principalmente através da patente de novos medicamentos. Tais patentes permitem o monopólio da empresa desenvolvedora do produto sobre o mesmo durante um período determinado. A possibilidade de práticas abusivas a partir deste monopólio leva as autoridades a tomarem medidas para controle de preços e para garantirem a finitude da patente. No entanto, os Estados Unidos e a União Européia vêm pressionando os demais países para o estabelecimento de novas medidas, que vão além do Acordo TRIPS, como o sigilo do registro de medicamen] => 0 ) ) ) [hasID] => Array ( [nn] => Array ( [0] => Array ( [oai:ojs.reciis.icict.fiocruz.br:article/848] => 0 ) ) ) [hasRegisterId] => Array ( [pt] => Array ( [0] => Array ( [https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848] => 0 ) [1] => Array ( [10.3395/reciis.v2i2.848] => 0 ) ) ) [hasSource] => Array ( [pt] => Array ( [0] => Array ( [Revista Eletrônica de Comunicação, Informação e Inovação em Saúde; v. 2, n. 2 (2008)] => 0 ) ) [nn] => Array ( [0] => Array ( [1981-6278] => 0 ) ) ) [hasTitle] => Array ( [en] => Array ( [0] => Array ( [The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy] => 0 ) ) [pt] => Array ( [0] => Array ( [A extensão da propriedade intelectual através do sigilo do registro de medicamentos: empecilhos à política de medicamentos genéricos] => 0 ) ) ) [hasUrl] => Array ( [pt] => Array ( [0] => Array ( [https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848/1490] => 0 ) [1] => Array ( [https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848/1662] => 0 ) ) ) [prefLabel] => Array ( [pt] => Array ( [0] => Array ( [Oai:ojs.reciis.icict.fiocruz.br:article/848#00086] => 0 ) ) ) )
Loading ...